Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

Using Fragment-Based Approaches to Discover New Antibiotics

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

A fragment based competitive 19F LB‐NMR platform for hotspot directed ligand profiling

Design and Crystallographic Screening of a Highly Sociable and Diverse Fragment Library Towards Novel Antituberculotic Drugs

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

Discovery of fragments that target key interactions in the signal recognition particle (SRP) as potential leads for a new class of antibiotics

Covalent fragment-based drug discovery for target tractability

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

Development of a Fragment-Based Machine Learning Algorithm for Designing Hybrid Drugs Optimized for Permeating Gram-Negative Bacteria

A high-throughput phenotypic screen combined with an ultra-large-scale deep learning-based virtual screening reveals novel scaffolds of antibacterial compounds

antibacTR: dynamic antibacterial-drug-target ranking integrating comparative genomics, structural analysis and experimental annotation

Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches

Ligand and Target Discovery by Fragment-Based Screening in Human Cells

Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae